What is the recommended dose of Tamiflu (oseltamivir) for treating influenza?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tamiflu (Oseltamivir) Dosing for Influenza

For adults and adolescents ≥13 years, the recommended dose is 75 mg orally twice daily for 5 days for treatment, initiated within 48 hours of symptom onset. 1, 2, 3

Treatment Dosing

Adults and Adolescents (≥13 years)

  • 75 mg orally twice daily for 5 days (equivalent to 12.5 mL of oral suspension twice daily if using liquid formulation) 1, 2, 3
  • Treatment should be initiated within 48 hours of symptom onset for maximum effectiveness, though should not be withheld in high-risk or hospitalized patients presenting beyond 48 hours 1, 2, 4

Pediatric Patients (≥12 months to 12 years)

Weight-based dosing twice daily for 5 days: 1, 3

  • ≤15 kg (≤33 lb): 30 mg twice daily (5 mL twice daily)
  • >15-23 kg (>33-51 lb): 45 mg twice daily (7.5 mL twice daily)
  • >23-40 kg (>51-88 lb): 60 mg twice daily (10 mL twice daily)
  • >40 kg (>88 lb): 75 mg twice daily (12.5 mL twice daily)

Infants (<12 months)

Age-based dosing twice daily for 5 days: 1, 4

  • 9-11 months: 3.5 mg/kg per dose twice daily
  • Term infants 0-8 months: 3 mg/kg per dose twice daily
  • Infants as young as 2 weeks: 3 mg/kg per dose twice daily 1, 3

Preterm Infants

Postmenstrual age-based dosing (gestational age + chronological age) twice daily: 1, 4

  • <38 weeks postmenstrual age: 1.0 mg/kg twice daily
  • 38-40 weeks postmenstrual age: 1.5 mg/kg twice daily
  • >40 weeks postmenstrual age: 3.0 mg/kg twice daily

The lower doses for preterm infants are critical due to immature renal function, and failure to adjust can lead to toxicity. 1

Prophylaxis Dosing

Post-Exposure Prophylaxis

Initiate within 48 hours following close contact with an infected individual: 1, 2

Adults and Adolescents (≥13 years):

  • 75 mg orally once daily for 10 days (12.5 mL once daily if using suspension) 1, 2, 3

Pediatric Patients (1-12 years): Same weight-based doses as treatment, but once daily for 10 days: 1, 3

  • ≤15 kg: 30 mg once daily (5 mL once daily)
  • 15-23 kg: 45 mg once daily (7.5 mL once daily)

  • 23-40 kg: 60 mg once daily (10 mL once daily)

  • 40 kg: 75 mg once daily (12.5 mL once daily)

Infants (3-11 months):

  • 3 mg/kg once daily for 10 days 1, 3
  • Prophylaxis is NOT recommended for infants <3 months unless the situation is judged critical due to limited safety data 1

Seasonal Prophylaxis

  • Duration can be extended up to 6 weeks during a community outbreak 2, 3
  • In immunocompromised patients, may continue up to 12 weeks 3

Renal Impairment Adjustments

For patients with creatinine clearance 10-30 mL/min: 1, 3

Treatment:

  • 75 mg once daily (instead of twice daily) for 5 days 1

Prophylaxis:

  • 30 mg once daily for 10 days OR 75 mg every other day for 10 days (5 total doses) 1, 2

Oseltamivir is NOT recommended for end-stage renal disease patients not undergoing dialysis. 1, 3

Administration Considerations

Formulations Available

  • Capsules: 30 mg, 45 mg, and 75 mg 1, 4
  • Oral suspension: 6 mg/mL concentration when reconstituted 1, 4, 3

Administration Tips

  • Can be taken with or without food, though taking with meals significantly improves gastrointestinal tolerability 1, 2, 4
  • Capsules can be opened and contents mixed with liquid if patient cannot swallow whole 1, 2
  • Nausea and vomiting occur in approximately 5-15% of patients but are typically mild and transient 1

Drug Interaction Warning

  • Avoid live attenuated influenza vaccine (LAIV) within 48 hours before oseltamivir use 1
  • Do not use oseltamivir for 14 days after LAIV vaccination unless medically necessary 1, 2

Critical Clinical Pearls

  • The 48-hour window for treatment initiation is crucial for maximum benefit, with earlier initiation associated with faster resolution 1, 2, 5
  • However, treatment should NOT be withheld in high-risk or hospitalized patients presenting beyond 48 hours 2
  • For preterm infants, postmenstrual age-based dosing is essential to avoid toxicity—do not use standard infant dosing 1, 4
  • Oseltamivir is safe in pregnancy at standard adult doses throughout all trimesters and is preferred over zanamivir 2

References

Guideline

Oseltamivir Dosage and Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Oseltamivir Treatment and Prophylaxis Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Oseltamivir and Peramivir Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.